← Back to Search

Hormone Therapy

Carbetocin Nasal Spray for Prader-Willi Syndrome

Phase 3
Waitlist Available
Research Sponsored by ACADIA Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Must not have
Active psychotic symptoms, a history of psychotic symptoms, or a psychotic disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 36 months
Awards & highlights

Summary

This trial will look at how safe and well-tolerated a nasal spray called carbetocin is in people with PWS over a long period of time.

Who is the study for?
This trial is for individuals with Prader-Willi Syndrome, particularly those who experience hyperphagia or binge eating. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may need to have a confirmed diagnosis of the condition.
What is being tested?
The study is testing the long-term safety and tolerability of a nasal spray containing carbetocin (3.2 mg taken three times daily) in subjects with Prader-Willi Syndrome to see if it can help manage their symptoms.
What are the potential side effects?
While specific side effects are not listed here, carbetocin could potentially cause nasal discomfort or irritation, headaches, nausea, or other reactions related to hormone changes since it's similar to oxytocin.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had or currently have symptoms of a psychotic disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), withdrawals due to adverse events (AEs), potentially clinically important changes in other safety assessments, device incidents or device malfunctions

Trial Design

1Treatment groups
Experimental Treatment
Group I: Drug: CarbetocinExperimental Treatment1 Intervention
Carbetocin nasal spray 3.2 mg three times daily (TID)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carbetocin
2019
Completed Phase 4
~8290

Find a Location

Who is running the clinical trial?

ACADIA Pharmaceuticals Inc.Lead Sponsor
47 Previous Clinical Trials
11,436 Total Patients Enrolled
1 Trials studying Prader-Willi Syndrome
170 Patients Enrolled for Prader-Willi Syndrome
~107 spots leftby May 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top